- RNAC Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-3 Filing
Cartesian Therapeutics (RNAC) S-3Shelf registration
Filed: 11 Aug 17, 12:00am
Exhibit 12.1
STATEMENT REGARDING THE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED SHARE DIVIDENDS FOR THE YEARS ENDED DECEMBER 31, 2014, 2015 AND 2016 AND THE SIX MONTHS ENDED JUNE 30, 2017
(dollars in thousands)
|
| Year Ended December 31, |
| Six Months Ended June 30, |
| ||||||||
|
| 2014 |
| 2015 |
| 2016 |
| 2017 |
| ||||
Fixed Charges: |
|
|
|
|
|
|
|
|
| ||||
Interest expense on indebtedness |
| $ | 552 |
| $ | 1,031 |
| $ | 1,242 |
| $ | 579 |
|
Non-cash interest expense and other |
| — |
| (83 | ) | 12 |
| — |
| ||||
Interest expense on portion of rent expense representative of interest |
| 464 |
| 443 |
| 517 |
| 307 |
| ||||
Total fixed charges |
| $ | 1,016 |
| $ | 1,391 |
| $ | 1,771 |
| $ | 886 |
|
Preferred stock dividends |
| $ | 4,951 |
| $ | 7,335 |
| $ | 4,566 |
| $ | — |
|
|
|
|
|
|
|
|
|
|
| ||||
Earnings (loss): |
|
|
|
|
|
|
|
|
| ||||
Net loss |
| $ | (12,880 | ) | $ | (25,174 | ) | $ | (36,210 | ) | $ | (31,101 | ) |
Fixed charges per above |
| 1,016 |
| 1,391 |
| 1,771 |
| 886 |
| ||||
Adjusted earnings (loss) |
| $ | (11,864 | ) | $ | (23,783 | ) | $ | (34,439 | ) | $ | (30,215 | ) |
|
|
|
|
|
|
|
|
|
| ||||
Deficiency of earnings available to cover fixed charges |
| $ | (12,880 | ) | $ | (25,174 | ) | $ | (36,210 | ) | $ | (31,101 | ) |
Ratio of earnings (loss) to fixed charges |
| N/A |
| N/A |
| N/A |
| N/A |
| ||||
Deficiency of earnings available to cover fixed charges and preferred stock dividends |
| $ | (17,831 | ) | $ | (32,509 | ) | $ | (40,776 | ) | $ | (31,101 | ) |
Ratio of earnings (loss) to fixed charges and preferred stock dividends |
| N/A |
| N/A |
| N/A |
| N/A |
|